It provides automatic Part D coverage for FDA-approved weight loss medications (Wegovy, Zepbound, and Foundayo) at a $50 monthly copay, regardless of whether you have a secondary qualifying indication
In 2025, the company reported a -1.73% YoY (Jan-Dec25) decline in revenue, reflecting portfolio dynamics: Entyvio ($6.14B) continues to anchor growth in inflammatory bowel disease, Takhzyro ($1.44B) shows steady momentum in rare diseases, while Gattex/Revestive ($913.56M) remains a solid contributor in gastrointestinal disorders partially offset by generic pressure and loss of exclusivity in some legacy products
Our medical team customizes Semaglutide treatments as part of a comprehensive wellness plan
Thank u so much I will be a loyal customer until i cant be no more
In the UK, it is illegal to purchase retatrutide for cosmetic use
Open communication with your healthcare team ensures that both diabetes control and quality of life are optimised during treatment